Glaxo’s Tres Cantos Open Lab Trawls For Answers To Neglected Diseases
Tres Cantos, Spain facility hopes to move molecules into clinical research in 2013/2014. Wellcome Trust has just pledged £5 million to help support the lab’s open R&D programs.
You may also be interested in...
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.
Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.